Common use

Tenofovir/Emtricitabine is a powerful fixed-dose combination antiretroviral medication prescribed for two primary purposes: the treatment of HIV-1 infection as part of combination antiretroviral therapy (ART), and for pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals. Both tenofovir disoproxil fumarate and emtricitabine belong to the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) class. They work synergistically by blocking the HIV reverse transcriptase enzyme, which is essential for viral replication. By inhibiting this enzyme, the combination prevents HIV from copying its genetic material, effectively reducing viral load in infected patients and providing a protective barrier against new infection in PrEP users. This dual-NRTI backbone forms the foundation of most modern HIV treatment regimens and is recommended by the WHO and major clinical guidelines. Buy Tenofovir Emtricitabine online at dutypills.ovh for affordable, genuine antiretroviral therapy with discreet worldwide delivery.

Dosage and direction

Tenofovir/Emtricitabine is taken as one tablet once daily, with or without food. Tablets should be swallowed whole with water. For HIV treatment, it must always be used in combination with other antiretroviral agents — never as monotherapy. For PrEP, it is taken as a single daily tablet in combination with safer sex practices. The dosage is determined by your healthcare provider based on whether the medication is being used for treatment or prevention, along with your kidney function and body weight. Regular monitoring of kidney function (serum creatinine and estimated GFR), HIV viral load, CD4+ cell counts, and hepatitis B status is recommended throughout therapy. Take the medication at the same time each day for optimal drug levels and adherence.

Precautions

Before starting Tenofovir/Emtricitabine, inform your doctor if you have kidney disease or reduced renal function, liver disease (especially hepatitis B co-infection), osteoporosis or low bone mineral density, a history of lactic acidosis, or if you are pregnant or breastfeeding. Tenofovir can cause kidney toxicity and decreased bone mineral density with long-term use, so regular renal function monitoring and bone density assessments may be recommended. Stay well hydrated throughout treatment and promptly report any unusual muscle pain, weakness, bone pain, or changes in urination. Do not discontinue therapy without consulting your healthcare provider — in patients co-infected with hepatitis B, abrupt cessation may trigger severe hepatic flares. For PrEP users, it is essential to confirm HIV-negative status before starting and every 3 months during use, as taking PrEP while unknowingly HIV-positive can lead to drug resistance.

Contraindications

Do not use Tenofovir/Emtricitabine if you are allergic to tenofovir, emtricitabine, or any component of the tablet formulation. This medication should be used with extreme caution — or alternative agents considered — in patients with severe kidney impairment (creatinine clearance below 30 mL/min), as the drug is primarily eliminated through the kidneys. It is not recommended for PrEP in individuals with unknown or positive HIV status.

Possible side effect

Common side effects include headache, nausea, diarrhea, fatigue, dizziness, insomnia, abnormal dreams, and mild skin rash. Some patients may experience skin discoloration (hyperpigmentation), particularly with emtricitabine. Serious side effects requiring immediate medical attention include nephrotoxicity (decreased urine output, swelling in ankles, unexplained fatigue), lactic acidosis (unusual muscle pain, difficulty breathing, stomach pain with nausea and vomiting, cold or blue skin), severe hepatomegaly with steatosis (liver enlargement), significant bone density loss leading to fractures, and immune reconstitution inflammatory syndrome (IRIS). Seek emergency medical care if you experience any signs of these serious conditions.

Drug interaction

Tenofovir/Emtricitabine may interact with other nephrotoxic drugs (aminoglycosides, amphotericin B, cidofovir, vancomycin), didanosine (increases didanosine toxicity), NSAIDs, high-dose or chronic aspirin, acyclovir, valacyclovir, ganciclovir, and other medications that affect kidney function or are renally eliminated. Concurrent use of multiple tenofovir-containing products must be avoided. Always provide your healthcare provider with a complete list of all medications, supplements, and herbal products you are taking to prevent harmful drug interactions.

Missed dose

If a dose is missed, take it as soon as you remember on the same day. If it is near the time of your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not double the dose. For both HIV treatment and PrEP, consistent daily adherence is critical — missed doses reduce effectiveness and, in treatment patients, may promote viral resistance.

Overdose

Overdose of Tenofovir/Emtricitabine may cause nausea, vomiting, fatigue, dizziness, or kidney problems. Seek immediate medical attention or contact a poison control center if overdose is suspected. Emtricitabine can be partially removed by hemodialysis, while tenofovir is efficiently removed by hemodialysis. Supportive care with monitoring of renal function and vital signs is the standard approach.

Storage

Store Tenofovir/Emtricitabine at controlled room temperature between 68°F and 77°F (20°C to 25°C), protected from moisture, heat, and direct light. Keep tablets in their original container with the cap tightly closed. Store securely out of the reach of children and pets.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.